Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Lymphoma progression"'
Autor:
Yangyang Ding, Keke Huang, Cheng Sun, Zelin Liu, Jinli Zhu, Xunyi Jiao, Ya Liao, Xiangjiang Feng, Jingjing Guo, Chunhua Zhu, Zhimin Zhai, Shudao Xiong
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Bruton tyrosine kinase inhibitor (BTKi) combined with rituximab-based chemotherapy benefits diffuse large B-cell lymphoma (DLBCL) patients. However, drug resistance is the major cause of relapse and death of DLBCL. In this study, we conducte
Externí odkaz:
https://doaj.org/article/fa6ebc2c7e2b45e7adecf4864d64bcbb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Luis F. Oñate-Ocaña, Mayra Ponce-Martínez, Lucia Taja-Chayeb, Olga Gutiérrez-Hernández, Alejandro Avilés-Salas, David Cantú-de-León, Alfonso Dueñas-González, Myrna Candelaria-Hernández
Publikováno v:
Revista de Investigación Clínica, Vol 73, Iss 6 (2021)
Background: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) m
Externí odkaz:
https://doaj.org/article/6513ee05ea0740fd8c68b39e553d4c10
Publikováno v:
British Journal of Haematology. 193:369-374
Summary Extra‐nodal marginal zone B‐cell lymphoma (MZBL) of mucosa‐associated lymphoid tissue is an indolent lymphoma mostly affecting the gastrointestinal tract. The lymphoma initially has small‐cell morphology (SC‐MZBL) and often arises i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383870ecaa5b3a001ce13932153378a4
https://doi.org/10.1111/bjh.17193
https://doi.org/10.1111/bjh.17193
Autor:
Myrna Candelaria-Hernández, Olga Gutiérrez-Hernández, Mayra Ponce-Martínez, Alejandro Avilés-Salas, David Cantú-de-León, Lucia Taja-Chayeb, Alfonso Dueñas-González, Luis F. Oñate-Ocaña
Publikováno v:
Revista de Investigación Clínica, Vol 73, Iss 6 (2021)
Background Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. Objective The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198db81cb4df947e5d0e9254fbbb0396
https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=377
https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=377
Autor:
Juan J. Borrero, Ana Julia Gonzalez, Empar Mayordomo‐Aranda, Ana Ruiz-Zorrilla, Carlos Perez Seoane, Miguel A. Piris, Blanca Gonzalez Farre, Raul Cordoba, Javier Lopez Jimenez, José Gómez Codina, Carlos Aliste, Eva Domingo-Domenech, Joaquín Sánchez, Marta Grande, Guillermo Rodríguez, Antonio Martinez Pozo, Belen Navarro, Socorro María Rodríguez-Pinilla, Angeles Bendaña, Cecilia Carpio, Carmen Montoto, Mónica García-Cosío, Fina Climent, Sonia González de Villambrosia, Josep Castellví, Carmen Bellas, Oscar Javier Blanco Muñez, Dolores Caballero
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Dipòsit Digital de la UB
Universidad de Barcelona
Biblos-e Archivo. Repositorio Institucional de la UAM
British Journal of Haematology
BRITISH JOURNAL OF HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Scientia
instname
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Dipòsit Digital de la UB
Universidad de Barcelona
Biblos-e Archivo. Repositorio Institucional de la UAM
British Journal of Haematology
BRITISH JOURNAL OF HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Scientia
We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0ee5d4df1db1c08677e8e93184f52c
http://hdl.handle.net/10261/265101
http://hdl.handle.net/10261/265101
Autor:
Ahmet Kürşad GÜNEŞ, Murat ÇINARSOY
Publikováno v:
Volume: 8, Issue: 3 172-178
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
Hodgkin’s Lymphoma constitutes 10% of all the lymphomas and the 0.6% of adult cancers and owns a high treatment success. Our study aims to evaluate the treatment responses in the early Hodgkin’s Lymphoma and to determine factors that may have an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc06a874b3df58a2572ea40983f3cff7
https://dergipark.org.tr/tr/pub/muskutd/issue/67210/775295
https://dergipark.org.tr/tr/pub/muskutd/issue/67210/775295
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jonathan W. Friedberg, Michael Crump, Ole V. Gadeberg, Oliver W. Press, Pier Luigi Zinzani, Akiko Chai, Laurie H. Sehn, Swaminathan Padmanabhan Iyer, Tara Baetz, Günter Fingerle-Rowson, Gianluca Gaidano, M. Dolores Caballero, Andre Goy, Andrew D. Zelenetz, Rena Buckstein, Giovanni Martinelli, Deniz Sahin, Luis Fayad, Branimir Jakšić, Fritz Offner
Publikováno v:
Sehn, L H, Goy, A, Offner, F C, Martinelli, G, Caballero, M D, Gadeberg, O, Baetz, T, Zelenetz, A D, Gaidano, G, Fayad, L E, Buckstein, R, Friedberg, J W, Crump, M, Jaksic, B, Zinzani, P L, Iyer, S P, Sahin, D, Chai, A, Fingerle-Rowson, G & Press, O W 2015, ' Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma : Final Analysis of the GAUSS Study ', Journal of Clinical Oncology, vol. 33, no. 30, pp. 3467-3474 . https://doi.org/10.1200/JCO.2014.59.2139
Purpose Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c126dca13ac1f3346a6ad595ba7c41
https://pubmed.ncbi.nlm.nih.gov/26282650
https://pubmed.ncbi.nlm.nih.gov/26282650